PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29344794-9 2018 The company submitted an individual patient simulation model to estimate the cost-effectiveness of ticagrelor 60 mg BID + ASA versus ASA only. Ticagrelor 99-109 BH3 interacting domain death agonist Homo sapiens 116-119 29344794-18 2018 In its final guidance, the AC recommended treatment with ticagrelor 60 mg BID + low-dose ASA for secondary prevention of atherothrombotic events in adults who have had an MI and are at increased risk of atherothrombotic events. Ticagrelor 57-67 BH3 interacting domain death agonist Homo sapiens 74-77 28300867-2 2017 This study aimed to determine whether ticagrelor 60 mg twice daily (bid) provided potent and consistent platelet inhibition in patients with vs without diabetes in the PEGASUS-TIMI 54 platelet function substudy. Ticagrelor 38-48 BH3 interacting domain death agonist Homo sapiens 68-71 28300867-5 2017 In patients treated with ticagrelor 60 mg bid, on-treatment platelet reactivity to ADP, as determined by light transmission aggregometry (LTA), VerifyNow and VASP, was similar in patients with vs without diabetes (LTA post-dose, ADP 20 microM: 29 +- 14 vs 34 +- 10 %, respectively; p = 0.19). Ticagrelor 25-35 BH3 interacting domain death agonist Homo sapiens 42-45 28300867-6 2017 A consistent inhibitory effect of ticagrelor 60 mg bid was observed pre- and post-dose regardless of diabetes status, even in insulin-treated patients. Ticagrelor 34-44 BH3 interacting domain death agonist Homo sapiens 51-54 28300867-10 2017 In conclusion, ticagrelor 60 mg bid is equally effective at reducing platelet reactivity in patients with and without diabetes, yielding a consistently high level of platelet inhibition regardless of diabetes status. Ticagrelor 15-25 BH3 interacting domain death agonist Homo sapiens 32-35 28554486-9 2017 In conclusion, low-dose ticagrelor treatment, either with 90 mg QD or 45 mg BID, was associated with a more potent antiplatelet effect compared with clopidogrel treatment and once daily dose provided similar antiplatelet effect but favorable effect on optimal platelet inhibition compared with twice daily dose. Ticagrelor 24-34 BH3 interacting domain death agonist Homo sapiens 76-79 24935072-6 2014 Mean final-extent IPA was greater with ticagrelor 90 mg bid versus ticagrelor 45 mg bid and with both ticagrelor doses versus clopidogrel. Ticagrelor 39-49 BH3 interacting domain death agonist Homo sapiens 56-59